By Connor Hart
Shares of Insmed rose after the company disclosed what it called positive topline results from a study of its treatment for pulmonary arterial hypertension, or high blood pressure in the lungs.
The stock jumped 20%, to $85, in pre-market trading Tuesday. Through Monday's close, shares have gained 18% in the past year.
The biopharmaceutical company said its study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, met its primary endpoint and all secondary efficacy endpoints.
Based on the results of the study, Insmed said it will immediately engage with the Food and Drug Administration about a Phase 3 trial design.
The company plans to start a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease before the end of the year, as well as a Phase 3 trial in patients with pulmonary arterial hypertension in early 2026.
"The statistically significant and clinically meaningful results shown with TPIP in pulmonary arterial hypertension mark a potential breakthrough for patients and the future of prostanoid therapy," Chief Product Strategy Officer Gene Sullivan said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 10, 2025 08:38 ET (12:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。